Inbrija Will Be an Inhaled "On Demand" Med for Parkinson's Disease

Inbrija (in-BREE-jah) will be the first INHALED levodopa for adults with Parkinson's disease.

Think of Inbrija as a fast-acting "on demand" levodopa. It starts to work in about 10 minutes...and lasts about an hour.

Inbrija won't replace daily meds. Instead, it'll be used as needed to treat "off" episodes...when scheduled carbidopa/levodopa (Sinemet, etc) wears off between doses and symptoms (rigidity, tremor, etc) return.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 120+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote